Fewer than 10% of patients who could benefit from GLP-1 drugs such as Wegovy are able to get them, states the WHO as it issues its inaugural advice on the therapies.
Given over a billion individuals worldwide now obese, it is advocating for more widespread and fairer availability to this class of drugs.
Per forecasts, over two billion are projected to be obese by 2030 without intervention.
"Our latest guidelines acknowledges that obesity is a lifelong illness that can be addressed with comprehensive and lifelong care," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are major obstacles to broad availability to the injections that can help people shift substantial body mass, notes the agency.
Skinny Jab Scarcity
Even under the current most optimistic outlook, the manufacturing of these medications might only reach about 100 million people – fewer than 10% of the global need, per the health organization.
The advice encourages governments and firms to expand availability, by strategies including licensing agreements.
Exclusive production rights on a key compound – the main component of the drug Wegovy – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Jabs Function
These medications imitate a natural hormone to slow digestion, suppress the appetite and boost the sense of being full so individuals reduce food intake.
Patients commonly see weight reduction within a few weeks of commencing the weekly injections.
Research indicates people may regain a significant portion within a year of discontinuing the medication, as their typical hunger come back.
Being above a healthy weight increases your chance for experiencing medical conditions, such as type 2 diabetes, cardiovascular issues, stroke, and specific cancers.
Obesity concerns people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.
